跳至主要内容
临床试验/IRCT2017101536801N1
IRCT2017101536801N1招募中未知

Effect of Spironolacton on Choroidal Vascular Index in Patients with Central Serous Chorioretinopathy

Zahedan University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • All patients with central serous chorioretinopathy, whose condition has just been diagnosed and who have not received any treatment.
  • Exclusion criteria: Patients whohave been received any treatment for central serous chorioretinopathy, including intravitreal injection of bevasizumab, laser therapy, photodynamic therapy, and drug treatment; Failure to refer patients for follow-up treatment; Drug-related complications requiring drug discontinuation; Disagreement with the proposed treatment

排除标准

  • 未提供

研究者

发起方
Zahedan University of Medical Sciences

相似试验